ITF HELLAS

Founded in 1938 in Milan, Italfarmaco has left a compelling mark on the national and international pharmaceutical landscape. From its establishment until the 1970s, the company steadily solidified its position, emerging as a key player in the industry. With a robust franchise in thrombosis and cardiovascular areas, Italfarmaco gained recognition as a force to be reckoned with in the Italian mid-market segment. But its story didn't end there.

In 1976, Dr. Gastone De Santis joined the company, acquiring a stake and setting the stage for transformative leadership combining his passion for research and managerial activity. By 1980, he had assumed full control, becoming the chairman of the board of directors. That same year, his son, Francesco De Santis, stepped into the spotlight at just twenty-five years old. As managing director, and then as appointed Chairman, Francesco De Santis spearheaded an ambitious internationalization process that continues to this day.

Italfarmaco's global expansion took various forms—licensing contracts, collaboration agreements, direct presence establishment and strategic acquisitions.

In 1991, the founding of Italfarmaco S.A. in Spain marked a pivotal moment, kicking-off the company's expansion across Europe, the Americas, and Asia. Throughout this journey, Italfarmaco's resolute focus on research and development has been the cornerstone of its success, with the consolidation of its footprints in several therapeutic areas such as women's health and the focus on addressing significant unmet medical needs in rare diseases.

Today, Italfarmaco stands as a patient and innovation oriented, bridging borders and working in advancing healthcare and quality of life.